Table 1 |
||||
| Baseline characteristics of participants | ||||
| Control NA= 12 | Intervention NB= 16 | P value (A-B) | ||
| Demographics | ||||
| Age (y)1 | 81.8 (7.1, 71–94) | 85.1 (6.7, 70–98) | 0.233 | |
| Gender | Male:Female | 5:7 | 7:9 | 0.609 |
| Ethnicity | White British | 12 (100%) | 16 (100%) | - |
| Care Home Type2 | N:R:D | 5:7:0 | 3:10:3 | 0.171 |
| Body Mass Index1 | 25.5 (4.6, 20.8-36.4) | 27.7 (4.8, 19.5-35.9) | ||
| Heart failure | ||||
| Heart Failure3 | Confirmed:New | 6:6 | 9:7 | 1.000 |
| NYHA4 class | I:II:III:IV | 5:4:1:1 | 10:1:4:1 | 0.213 |
| Ejection Fraction (mean %, SD) | 43 (6.3) | 33 (1.4) | 0.146 | |
| Total no of co-morbidities (mean, SD)5 | 4.67 (2.1) | 4.50 (1.5) | 0.319 | |
| Renal Function | ||||
| Urea Abnormal6 | 8 (75%) | 9 (56%) | 0.705 | |
| Creatinine Abnormal7 | 2 (17%) | 5 (31%) | 0.558 | |
| Prescribed drugs8 | ||||
| ACEi and β blocker | 3 (25%) | 6 (38%) | 0.687 | |
| ACEi | 6 (50%) | 7 (44%) | 1.000 | |
| β blocker | 5 (42%) | 9 (56%) | 0.704 | |
| Angiotensin Receptor Blocker | 0 (0%) | 0 (0%) | - | |
| Calcium Channel Blocker | 1 (8%) | 4 (25%) | 0.355 | |
| Diuretic | 8 (67%) | 9 (56%) | 0.705 | |
| Statin | 7 (58%) | 8 (50%) | 0.718 | |
| Digoxin | 4 (33%) | 1 (6%) | 0.133 | |
| Antiplatelet | 7 (58%) | 10 (63%) | 1.000 | |
| Spironolactone | 0 (0%) | 0 (0%) | - | |
| Bronchodilators | 4 (33%) | 2 (13%) | 0.354 | |
| Warfarin | 3 (25%) | 1 (6%) | 0.285 | |
| Non Steroidal Anti-Inflammatory Drugs | 0 (0%) | 1 (6%) | 1.000 | |
| Total no of prescribed drugs (mean, SD) | 10.3 (3.4) | 9.5 (4.7) | 0.287 | |
1 Mean (standard deviation, range).
2 Nursing:Residential:Dementia.
3 Confirmed cases pre-existed in general practice HF register records.
4 New York Heart Association [34].
5 From a predefined list of co-morbidities (MI, IHD, Hypertension, AF, valvular heart disease, diabetes, COPD, osteoarthritis, cognitive impairment).
6 Outside normal limits (2.5-7.0mmol/l).
7 Outside normal limits (50-110μmol/l).
8 As recorded in GP notes.
Hancock et al. BMC Geriatrics 2012 12:70 doi:10.1186/1471-2318-12-70
